GSK plc GSK announced that the U.S. Centers for Disease Control and Prevention’s (“CDC”) Advisory Committee on Immunization ...

Penmenvy is a combination of GSK's already-approved vaccines Bexsero and Menveo ... receive the recommended two-dose vaccination series, while around 32% receive at least one dose.

Vaccine recommended to help protect persons ... Important Safety Information for BEXSERO in the US The following is based on the US Prescribing Information for BEXSERO. Please consult the full ...

Penmenvy combines the antigenic components of GSK’s approved Bexsero and Menveo meningococcal vaccines to target five common invasive meningococcal disease (IMD)-causing serotypes (A, B, C, W and Y).

GSK announced two important endorsements from the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on ...

This second article in our series looking at some of the shortlisted candidates focuses on Novartis' meningococcal B vaccine Bexsero. Few infections will strike as much fear into a parent as ...

Thanks in part to research led by Bristol, the UK has played a leading role in the fight against the disease with its pioneering use of a vaccine – Bexsero – that is both effective at reducing cases ...

GlaxoSmithKline recently held a high-level scientific conference in conjunction with the launch of “Bexsero,” the first vaccine in Egypt approved by the Egyptian Drug Authority for the ...

The meningitis vaccine called Bexsero and licensed in about 35 countries, but not yet in Kenya, has been found to protect against gonorrhoea. “New evidence suggests that Bexsero which protects ...